Respiratory Syncytial Virus (RSV) Burden in Older Adults in Primary Care in The Netherlands

Launched by UMC UTRECHT · Mar 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the impact of Respiratory Syncytial Virus (RSV) infections in older adults who receive care from their primary doctors in the Netherlands. RSV is a common virus that can cause serious health issues in older adults, sometimes leading to hospital stays. The goal of the study is to better understand how RSV affects this age group, especially as new vaccines for RSV may soon be available. By using advanced testing methods, the researchers hope to identify RSV infections more accurately, which will help in planning for vaccination efforts.

To participate in this study, you need to be at least 60 years old and have a positive test for RSV. It's important that you can understand and communicate in English or the local language, and you should not have taken part in any other RSV treatment trials. If you join the study, you'll be asked to provide consent and follow specific guidelines throughout the research process. This study is currently looking for participants, and your involvement could contribute to important findings that may help improve care for older adults with RSV in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age (≥60 years of age)
• • RSV positive
• • Subject is willing and able to give informed consent for participation in the study
• • Subject is willing and able to adhere to protocol-specific procedures
• Exclusion Criteria:
• • Subject is not able to understand and communicate in the local language or English.
• • Previous or current participation in RSV interventional trial (vaccine, antivirals)